Related Experiment Videos

Sudden death in dilated cardiomyopathy

A H Wu1, S K Das

  • 1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109, USA.

Clinical Cardiology
|April 13, 1999
PubMed

Insights

Sudden death in dilated cardiomyopathy (DCM) is often caused by ventricular arrhythmias. While ACE inhibitors improve survival, the roles of newer drugs and devices for arrhythmias in DCM require further investigation.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Dilated cardiomyopathy (DCM) is a significant cause of heart failure and sudden cardiac death.
  • Arrhythmias, particularly ventricular arrhythmias, are a major contributor to mortality in DCM patients.

Purpose of the Study:

  • To review the role of arrhythmias in sudden death among patients with dilated cardiomyopathy.
  • To discuss current and emerging treatment strategies for managing arrhythmias in DCM.

Main Methods:

  • Comprehensive literature search of MEDLINE database (1985-present) and relevant article citations.
  • Analysis of studies on the pathophysiology, prognostic significance, and management of arrhythmias in DCM.

Main Results:

  • Ventricular arrhythmias are the primary cause of sudden death in DCM, with ventricular ectopy potentially indicating risk.
  • Autonomic nervous system and renin-angiotensin-aldosterone axis abnormalities contribute to ventricular arrhythmias.
  • Electrophysiologic studies and signal-averaged electrocardiography have uncertain roles in risk stratification.

Conclusions:

  • Ventricular tachyarrhythmia is the main pathophysiological mechanism for sudden death in DCM.
  • Angiotensin-converting enzyme inhibitors are crucial for improving overall mortality.
  • Ongoing research is evaluating amiodarone, angiotensin-receptor antagonists, beta-blockers, and implantable cardioverter-defibrillators for arrhythmia management in DCM.

Related Concept Videos